🇺🇸 FDA
Patent

US 11401322

Immunoglobulin chimeric monomer-dimer hybrids

granted A61KA61K38/00A61K47/60

Quick answer

US patent 11401322 (Immunoglobulin chimeric monomer-dimer hybrids) held by BIOVERATIV THERAPEUTICS INC. expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BIOVERATIV THERAPEUTICS INC.
Grant date
Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K38/00, A61K47/60, A61K47/642, A61K47/68